SUMMARY A randomized, double-blind comparison of nalbuphine 30 mg or 60 mg by mouth and dihydrocodeine 30 mg by mouth was conducted in 75 patients with moderate to severe pain after surgery for dental extractions under general anaesthesia. A significant reduction in pain intensity followed each treatment and persisted throughout the 4-h observation period after nalbuphine, but only for 3 h after dihydrocodeine was given. Reduction in pain intensity was significantly greater 2, 3 and 4 h after the use of nalbuphine 60 mg than following dihydrocodeine 30 mg, and the mean total pain intensity difference was greater following nalbuphine
for the initial treatment of postoperative pain. Before anaesthesia was induced the patients practised the use of a 10-cm horizontal linear analogue scale (LAS) ("None" to "Worst, unbearable"), for recording the degree of pain.
Anaesthesia was induced in the unpremedicated patients with thiopentone-approximately 4 mg kg" 1 i.v., followed by suxamethonium (1.5 mg kg" 1 ). The trachea was intubated and anaesthesia maintained using nitrous oxide in oxygen with clinically appropriate concentrations of enflurane. No analgesics were administered on the day of surgery, before the postoperative analgesic was given. When the patients requested pain relief after recovery from anaesthesia they were given oral medication randomized according to the number of their entry into the study and rendered double-blind by the use of a double-dummy technique.
Before medication the patients indicated the intensity of their pain (by LAS) and this assessment was repeated 0.5, 1, 2, 3 and 4h after medication, or until another analgesic was given. At each assessment after medication the assessor recorded an opinion regarding pain relief, grading it as 0, 1 (slight), 2 (moderate) 3 (good) or 4 (complete). Any response to non-specific questions regarding side-effects or discomfort was noted also. The intensity of side-effects was graded as mild, moderate or severe, their duration noted, and any medication required to treat them was recorded.
Alternative analgesic therapy was given immediately on demand to any patient who requested it and these patients were withdrawn from the study.
Statistical analysis
Pain intensity scores (LAS) were treated as parametric data and analysed (including piretreatment scores) by repeated measures analysis of variance (using BMDP2V [6] ). LAS values missing because of withdrawals from the study were replaced by values calculated by regressing the missing values on the existing pain intensity scores, and also on the pain relief scores using the BMDPAM algorithm [6] . The degrees of freedom for the error terms in the analysis of variance were reduced by the number of missing values involved in the term. For the missing pain relief gradings resulting from withdrawal from the trial, an extra category (withdrawn) was included, to allow the use of a continuation odds model for regression analysis (GLIM algorithm) [7] .
The Fisher-Tukey approach to avoid overstating the statistical significance of a posteriori tests was used. Duration of effect was assessed by use of the paired J-test to compare the 4-h assessments with pre-treatment values. Betweengroup comparisons of the predicted peak effect of the analgesics were made by comparing pain relief grades at the 2-h assessment, using the MannWhitney U test. In the case of patients who had already withdrawn from the study, the final grade that had been assessed was recorded for this time. Other categorical data were assessed using the Chi-squared test.
RESULTS
Fifteen of the 90 patients who entered the study were withdrawn before recording of the effects of the medication could start. Some of these vomited shortly after medication; others requested an injection because of severe pain. Full records were obtained for 75 patients: 27 received dihydrocodeine 30 mg, 24 nalbuphine 30 mg and 24 nalbuphine 60 mg. Demographic data are recorded in table I; the groups were similar in composition.
Pain intensity values are illustrated in figure  1 .
All the treatments provided some reduction in pain intensity for 3 h. At the 4-h assessment dihydrocodeine was no longer effective, whereas both doses of nalbuphine were still providing a significant reduction in pain intensity (P < 0.01; paired t test). The reduction in effectiveness of dihydrocodeine towards the end of the observation period is confirmed by the number of patients requiring additional analgesia. Only three patients who received nalbuphine 60 mg required an additional analgesic compared with nine in the group which received dihydrocodeine-eight of these after 3 h. All but five of the remaining patients in this group showed increasing pain between the 3-and 4-h assessments.
Nine patients who received nalbuphine 30 mg also required additional analgesia, eight before 2 h. However, on those occasions when nalbuphine 30 mg was effective, it worked effectively throughout the observation period. The initial mean pain intensity score for the nalbuphine 30 mg group (61.5) was significantly higher than those of the other groups (53 and 52.4, respectively) (P < 13.1* 16.0* 9.4* 0.05, t test), indicating the recruitment into this group of several patients with more severe pain than the general level observed. Indeed, the patients in the nalbuphine 30 mg group who required additional analgesia had an initial mean pain intensity score of 78.5. It appears to be inappropriate to treat pain of such high intensity with oral medication, and most of these patients required a parenteral opioid.
Because of the difference in pain intensity before medication, and the increased number of early withdrawals compared with the other groups, the nalbuphine 30 mg group was omitted from the between group comparisons of pain intensity and total pain intensity differences. Mean pain intensities (table II) were significantly (P < 0.05) lower in the nalbuphine-treated patients than in the dihydrocodeine-treated patients at 2, 3 and 4 h after medication. The total decrease in pain intensity scores was also greater in the nalbuphine group (P < 0.05). The percentage of patients in whom pain relief was assessed as complete or good is indicated in table III, together with the total pain relief scores that were recorded. Only in the nalbuphine 60 mg group did at least 50 % of the patients achieve these degrees of pain relief. Two hours after medication, nalbuphine 60 mg provided significantly better pain relief than dihydrocodeine (P < 0.01, Mann-Whitney U test).
The number and type of side-effects encountered are listed in table IV and were typically those caused by opioids. There was no statistical difference between the groups. One patient in each of the nalbuphine groups was treated (with an antiemetic) for side-effects before additional analgesics were administered.
DISCUSSION
The comparison made in the present study was primarily that between nalbuphine 60 mg and dihydrocodeine 30 mg and this showed statistical differences between the groups in favour of nalbuphine before withdrawals seriously affected the analysis. Most early withdrawals occurred in the group of patients who received nalbuphine 30 mg, but this observation may be related less to the ineffectiveness of this dose than to the fact that this group contained more patients with severe pain than the other groups, a quirk of random allocation. For these reasons this group was omitted from the analysis of variance used to compare the other groups but, as can be seen in figure 1 (mean pain intensity scores (including substituted values)) and table III (the pain relief obtained), nalbuphine 30 mg was at least as good an analgesic as dihydrocodeine 30 mg and, like the larger dose of nalbuphine, was still effective after 4 h, whereas dihydrocodeine was not.
The statistical assessment of duration of effect was made by comparing pain intensity before treatment with that at the end of the observation period using Student's paired t test. This method of analysis avoids the theoretical problems of assessing probability after multiple testing. For the same reason, between-group comparisons of pain relief were confined to the anticipated time of maximum effect (2 h). From previous experience it was not anticipated that the maximum effect of oral dihydrocodeine after surgery would appear earlier, and this biased this assessment in favour of nalbuphine. In the other analyses the FisherTukey approach was used to maintain at least a minimum statistical significance level when a large number of comparisons are made.
The results of the investigation indicate that nalbuphine by mouth reduces pain after dental surgery. However, whilst a dose of 30 mg is as effective as, and acts for longer than dihydrocodeine 30 mg, nalbuphine 60 mg is significantly more effective than dihydrocodeine, and was the only medication to produce good or complete pain relief in more than 50% of the patients who received it.
